Scarica l'app Stockscreener
167.56
1.78%
2.6755
Ascendis Pharma A S Adr Borsa (ASND) Ultime notizie
Banco Macro ADR Earns Relative Strength Rating Upgrade - Inkl
Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha
Novartis ADR Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Inkl
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Jump To 87 - Investor's Business Daily
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call - ACCESS Newswire
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView
Ascendis Pharma at TD Cowen Conference: Strategic Growth in Rare Diseases - Investing.com
Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com
Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com
Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga
Stocks To Watch: Kontoor Brands Sees RS Rating Rise To 84 - Inkl
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily
Stocks To Watch: Pony AI ADR Sees RS Rating Jump To 92 - Inkl
Ascendis Pharma's SWOT analysis: promising pipeline fuels stock potential - Investing.com
ASND’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise - Investing.com
Ascendis Pharma launches $25 million share buyback - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
Cantor Fitzgerald maintains Ascendis Pharma Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Ascendis Pharma Overweight rating - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - MSN
JPMorgan raises Ascendis Pharma target to $167, keeps Overweight - Investing.com
Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Wednesday - Defense World
Goldman Sachs retains Buy on Ascendis Pharma shares, cites legal action - Investing.com
BioMarin sues Ascendis Pharma over patent infringement - Investing.com
Ascendis Pharma stock falls on missed Skytrofa revenue forecast - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - MSN
European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN
UBS starts Ascendis Pharma stock at Buy, optimistic on upcoming launches - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN
Ascendis Pharma's SWOT analysis: stock poised for growth amid challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN
Ascendis Pharma target raised to $194 on positive trial results - Investing.com
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading - MSN
Ascendis Pharma's SWOT analysis: stock faces growth hurdles amid pipeline promise - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN
European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN
TD Cowen boosts Ascendis stock target, sees Q3 Skytrofa growth lagging but long-term outlook intact - Investing.com
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily
Ascendis reports positive 3-year hypoparathyroidism trial data - Investing.com
Ascendis Pharma launches $300 million public offering - Investing.com
Why This Small Biotech Is Hammering BioMarin Today - Investor's Business Daily
Citi maintains Ascendis Pharma stock at Buy, positive outlook ahead of pivotal trial data - Investing.com
Biotech Makes A Bearish Move On Drug-Pricing Fiasco - Investor's Business Daily
Ascendis Pharma secures $150 million royalty deal for YORVIPATH - Investing.com
3 George Soros stocks to turn $100 into $1,000 by 2025Finbold - Finbold - Finance in Bold
JPMorgan raises Ascendis Pharma stock target on drug approval - Investing.com
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains? - MSN
Ascendis Pharma ADR Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Biotech Surges After FDA, Finally, Approves Its Embattled Drug - Investor's Business Daily
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Jump To 81 - Investor's Business Daily
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):